Neuropace, Inc. (NPCE)
NASDAQ:NPCE
Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.09
-$0.66(-5.31%)
At close: 4:00 PM EST
$14.09
-$0.66(-5.31%)
Day’s Range― - ―
52-Week Range$7.56 - $19.60
Previous CloseN/A
Volume21.31K
Average Volume (3M)188.15K
Market Cap
$533.23M
Enterprise Value$619.59M
Total Cash (Recent Filing)$53.98M
Total Debt (Recent Filing)$70.46M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding34,093,746
10 Day Avg. Volume133,681
30 Day Avg. Volume188,151
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit7.95
Enterprise Value/Ebitda-44.77
Forecast
1Y Price Target
$19.75Price Target Upside40.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$99.95M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~82% adjusted gross margins indicate durable product-level profitability and pricing power for the RNS system. High margins provide structural support for future operating leverage as revenue scales, improving the odds of turning positive operating profit with disciplined SG&A and R&D.
FDA Approval: ECoG AssistantRegulatory approval of ECoG Assistant is a structural product expansion that converts NeuroPace's data advantage into an approved clinical tool. This broadens the addressable offering, strengthens clinician stickiness, and supports recurring service and platform revenue potential over the medium term.
Commercial Momentum & GuidanceRaised guidance and reported ~20% underlying RNS system growth reflect durable commercial traction: expanding prescribers, account penetration, and improved funnel conversion. Combined with operating leverage efforts, this momentum supports more predictable multi-quarter revenue scaling.
Bears Say
High Leverage / Compressed EquityElevated leverage and a compressed equity base materially increase financing and dilution risk. The thin capital cushion reduces flexibility to invest in commercialization or absorb setbacks, raising refinancing cost and vulnerability to adverse cash-flow shocks over the coming 2–6 months.
Negative Cash GenerationPersistent negative operating and free cash flow—though improved versus prior years—means the business still requires external funding to sustain growth and R&D. Continued cash burn limits runway, risks dilution or costly financing, and constrains investment pacing despite improving margins.
Reimbursement & Coverage UncertaintyWidespread commercial adoption of new indications (eg, IGE, pediatric) depends on payer policy development and case-by-case advocacy. Slow private payer adoption can materially delay revenue realization after regulatory wins, keeping procedure volumes and reimbursement timing volatile.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $7.56 and its highest was $19.60 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $533.23M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on May 12, 2026. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.098.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 34,093,746 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 0.063%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (40.17% Upside)
$19.75 (40.17% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.26%
12-Months-Change
Fundamentals
Return on Equity
-120.74%
Trailing 12-Months
Asset Growth
-10.26%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. is a U.S.-based medical technology firm. It specializes in the creation and distribution of the RNS system, an advanced brain-responsive neuromodulation device designed to manage medically intractable focal epilepsy. This innovative system delivers tailored, real-time therapy directly to the source of seizures. Furthermore, the RNS system continuously records brain activity, providing medical professionals with the capability to monitor patients both on-site and remotely. The company supplies its devices to hospitals for both initial surgical implantations and subsequent replacement procedures. NeuroPace, Inc. was founded in 1997 and maintains its corporate headquarters in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit RNS revenue growth (CFO reported ~20% YoY excluding DIXI), raised full-year guidance, improved adjusted EBITDA outlook, robust clinical data (NAUTILUS 18-month and 3-year focal outcomes), and tangible AI/product roadmap progress. Offsetting risks include the NAUTILUS primary endpoint nuance, IGE revenue timing and payer coverage uncertainty, seasonally lower cash, and ongoing need for reimbursement work. Overall, management presented disciplined investment and operating leverage alongside meaningful opportunities that outweigh near-term risks.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$19.75
▲(40.17% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
16.74% Insiders
9.77% Mutual Funds
42.19% Other Institutional Investors
16.12% Public Companies and
Individual Investors